Figure 1.
Distribution of clinical indications at the time of referral to array comparative genomic hybridisation (aCGH) testing among patients with 16p11.2 deletion and duplication. DYSMOR, dysmorphism; FTT, failure to thrive; MCA, congenital anomalies; MR/DD, mental retardation/developmental delay; SZ, seizures.